Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 11:57 ET | Source: Spherix Global Insights

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S....
October 20, 2025 07:00 ET | Source: BPGbio

BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease

New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain and creates new frontier for drug research
March 11, 2025 08:53 ET | Source: Research and Markets

Neurological Biomarkers: Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of PerkinElmer, Abbott Labs, Thermo Fisher Scientific, Banyan Biomarkers, Bio-Rad Labs & More

Dublin, March 11, 2025 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
February 27, 2025 16:15 ET | Source: Alumis Inc.

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
October 24, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
September 26, 2024 06:02 ET | Source: Research and Markets

Precision Neurodegenerative Disease Global Market Report 2024-2028: Key Growth Opportunities in GLP-1 RA and Insulin for AD and PD Patients and Neurotech-based Precision Therapies

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Precision Neurodegenerative Disease Market, Global, 2024-2028" report has been added to ResearchAndMarkets.com's offering.The rising global...
August 14, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
August 01, 2024 04:46 ET | Source: Research and Markets

Molecular Diagnostics for Neurodegenerative Diseases Technology Research Report 2024-2028 Featuring Synaps Dx, AgenT Biotech, Urvogelbio, Resonant, and Neurodex

Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028" report has been added to ResearchAndMarkets.com's...
July 31, 2024 09:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
March 28, 2024 17:56 ET | Source: Research and Markets

United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...